Retinol-binding protein 4 in polycystic ovary syndrome-association with steroid hormones and response to pioglitazone treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1229-1235

  Aigner, Elmar ^a   Bachofner, Nora ^c   Klein, Kerstin ^b   De Geyter, Christian ^d   Hohla, Florian ^a   Patsch, Wolfgang ^b   Datz, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HYDROXYPROGESTERONE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIOGLITAZONE; PLACEBO; PRASTERONE SULFATE; RETINOL BINDING PROTEIN 4; STEROID HORMONE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIRSUTISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 65249106724     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2156     Document Type: Article

References (49)

1. Pasquali R, Gambineri A, Pagotto U 2006 The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113:1148-1159
2. Essah PA, Nestler JE 2006 Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 86(Suppl 1):S18-S19
3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Lobo RA, Carmina E 2000 The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132:989-993
5. Chang RJ 2007 The reproductive phenotype in polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 3:688-695
6. Essah PA, Wickham EP, Nestler JE 2007 The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50:205-225
7. Taksali SE, Caprio S, Dziura J, Dufour S, Cali AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R 2008 Highvisceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 57:367-371
8. Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, Capeau J, Fermon C, Valat AS, Lascols O, Hecart AC, Pigny P, Delemer B, Vigouroux C, Wemeau JL 2008 Fertility and obstetrical complications in women with LMNA- related familial partial lipodystrophy. J Clin Endocrinol Metab 93:2223-2229
9. Hoffman LK, Ehrmann DA 2008 Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 4:215-222
10. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy 2nd PF, FitzpatrickLA 2003 Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2562-2568
11. Pasquali R, Gambineri A 2006 Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 154:763-775
12. Iuorno MJ, Nestler JE 2001 Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28:153-164
13. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS 2008 The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93:4299 -4306
14. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876 -1880
15. Brettenthaler N, De Geyter C, Huber PR, Keller U 2004 Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3835-3840
16. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga- Troncoso G, Parra A 2005 Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with poly- cystic ovary syndrome. J Clin Endocrinol Metab 90:1360 -1365
17. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS 2008 Pleiotropic effects of thia zolidinediones. Expert Opin Pharmacother 9:1087-1108
18. Phillips LK, Prins JB 2008 The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 10:156-164
19. Bulcao C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF 2006 The new adipose tissue and adipocytokines. Curr Diabetes Rev 2:19 -28
20. Antuna-Puente B, Feve B, Fellahi S, Bastard JP 2008 Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 34:2-11
21. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, JanssonPA, SmithU, Kahn BB 2006 Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552-2563
22. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E, Elsenbruch S 2005 Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 153: 853-860
23. Tilg H, Moschen AR 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783
24. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C 2008 The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf) 69:52-60
25. Galluzzo A, Amato MC, Giordano C 2008 Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 18:511-518
26. Cervero A, Dominguez F, Horcajadas JA, Quinonero A, Pellicer A, Simon C 2006 The role of the leptin in reproduction. Curr Opin Obstet Gynecol 18: 297-303
27. Orio Jr F, Palomba S, Cascella T, MilanG, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R 2003 Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2619 -2623
28. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, Pugeat M 2003 Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:3626 - 3631
29. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J 2004 Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 27:528 -534
30. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C 2004 Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 61:738 -746
31. Gulcelik NE, Aral Y, Serter R, Demir Y, Culha C 2006 Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 22:511-515
32. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, Hermann AP 2006 Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 155:337-345
33. Tilg H, Moschen AR 2008 Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 114:275-288
34. Glintborg D, FrystykJ, Hojlund K, AndersenKK, HenriksenJE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M 2008 Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 68:165-174
35. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A 2003 Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18:1210 -1218
36. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654
37. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K 1999 Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71:323-327
38. Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I 2001 Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin- sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol 144:509 -515
39. Soldani R, Cagnacci A, Paoletti AM, Yen SS, Melis GB 1995 Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I in vitro. Fertil Steril 64:634 -637
40. Soldani R, Cagnacci A, YenSS 1994 Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol 131:641-645
41. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S, Gorska M 2007 Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 22:1824-1829
42. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS 2006 Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 91:5022-5028
43. Mohlig M, Weickert MO, Ghadamgahi E, Arafat AM, Spranger J, Pfeiffer AF, Schofl C 2008 Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. Eur J Endocrinol 158:517-523
44. Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ 2008 Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care 31:1427-1432
45. Hahn S, Backhaus M, Broecker-Preuss M, TanS, Dietz T, Kimmig R, Schmidt M, Mann K, Janssen OE 2007 Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. Eur J Endocrinol 157:201-207
46. Tan BK, Chen J, Lehnert H, Kennedy R, Randeva HS 2007 Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. J Clin Endocrinol Metab 92:2764 -2772
47. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L 2005 Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90:6099 -6105
48. Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L 2007 Interactions among peroxisome proliferator activated receptor-y, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 92:2232-2239
49. Avtanski DB PG, Strizhevsky M, Feng Y, Pareek A, Singh J, Singh N, Polskaya M, Rosenwaks Z, Seto-Young D, Poretsky L, Thiazolidinediones inhibit estrogen synthesis by interfering with androgen binding to aromatase. Program ofthe 90th Annual Meeting ofThe Endocrine Society, San Francisco, CA, 2008 (Abstract P2-44)